Solventum Opens $200 Million Innovation Hub in Eagan, Strengthening R&D Footprint

SOLV
April 02, 2026

Solventum Corporation opened a 250,000‑square‑foot Innovation Hub in Eagan, Minnesota, on April 1, 2026, marking the company’s first major facility investment since its 2024 spin‑off from 3M. The $200 million project is part of a broader $209 million expansion plan that is expected to be completed early in 2026.

The new hub consolidates Solventum’s research and development activities under one roof, bringing together its MedSurg, Dental Solutions and Health Information Systems businesses. By centralizing advanced materials and healthcare solutions work, the facility is designed to accelerate product development, shorten time‑to‑market, and foster cross‑segment collaboration.

Solventum’s leadership highlighted the strategic importance of the investment. CEO Bryan Hanson described the building as “like the Taj Mahal” and said, “This is where the ideation and innovation happens.” The comment underscores the company’s intent to create a culture of rapid experimentation and to attract top talent to the Minnesota region.

The project received approximately $13 million in support from the state of Minnesota through the Job Creation Fund and the Minnesota Investment Fund, and Governor Tim Walz proclaimed April 1 “Solventum Day.” The investment reflects Solventum’s commitment to maintaining a strong presence in Minnesota, where it employs more than 1,800 people.

Strategically, the hub aligns with Solventum’s goal of achieving 4‑5 % organic sales growth by 2028 and expanding operating margins to 23‑25 % in the same year. The facility is expected to enhance the company’s competitive position by enabling faster innovation cycles across its core segments and by reinforcing its focus on integrating health, material, and data science capabilities.

The opening of the Innovation Hub signals Solventum’s confidence in its long‑term growth strategy and its willingness to invest heavily in R&D infrastructure to sustain its competitive advantage in the med‑tech and digital health markets.

The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.